Posted on January 9, 2021 by Sitemaster
As we advised readers yesterday, a newly published study by Gregg et al. from the M. D. Anderson Cancer Center has given some clear indications that men diagnosed with lower-risk forms of prostate cancer who are initially managed on active surveillance (AS) can benefit — in terms of time to disease progression — from what is known as the Mediterranean-type diet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, disease, Mediterranean, progression, risk, surveillance | 4 Comments »
Posted on January 8, 2021 by Sitemaster
The abstract of a newly published study on the use of the Mediterranean diet (MD) by men on active surveillance (AS) for management of low-risk, localized prostate cancer states that … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, diet, low risk, Mediterranean, surveillance | 4 Comments »
Posted on November 25, 2020 by Sitemaster
Some 18 months ago we had written about the possible occurrence of spontaneous remissions in men on active surveillance (AS) for low-risk forms of prostate cancer. We were therefore very interested in a recent article closely related to this topic. … READ MORE..
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, biopsy, negative, remission, serial, spontaneous, surveillance | 14 Comments »
Posted on November 13, 2020 by Sitemaster
The following article was written by two of the founders of Active Surveillance Patients International (ASPI) under the title “Al Roker’s forecast: rising PSA and a radical prostatectomy” and distributed largely by e-mail. It is re-posted here with the permission of the authors. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: active, celebrity, Roker, surveillance | 4 Comments »
Posted on October 28, 2020 by Sitemaster
Perhaps unsurprisingly, your sitemaster was a little distracted on March 9 this year (by both the start of the COVID-19 chaos and by his birthday) and so he utterly missed what appears to be a rather important paper on the use of 5α-reductase inhibitors (5-ARIs) in men on active surveillance (AS) for management of low-risk forms of prostate cancer.
… READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 5-ARI, active, AS, Prevention, progression, surveillance | 2 Comments »
Posted on September 10, 2020 by Sitemaster
At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 3 Comments »
Posted on August 29, 2020 by Sitemaster
The Prostate Active Surveillance Study (PASS), initially funded by the Canary Foundation, is a multi-center research study for men with low-risk disease who have chosen active surveillance (AS) to manage their prostate cancer. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, AS, calculator, PASS, progression, risk, surveillance | Leave a comment »
Posted on August 12, 2020 by Sitemaster
If you weren’t able to take part in the “live” presentation by Dr. Peter Carroll on “The past, present and future of active surveillance (AS)”, you can now view this either here on YouTube or here on the UroToday web site. This is the first in a series of four live video programs on AS-related topics. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance | 2 Comments »
Posted on July 18, 2020 by Sitemaster
We have heard from Howard Wolinksy that he and others have been helping to put together a series of four webinars on different aspects of active surveillance (AS) for the management of favorable-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance, webinar | 1 Comment »
Posted on April 30, 2020 by Sitemaster
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
Posted on March 4, 2020 by Sitemaster
Jane Brody is an experienced journalist who writes regularly about issues related to health care in The New York Times. Your sitemaster regularly reads her columns because she does her homework with care and provides sound information for her readers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Brody, New York Times, screening, surveillance | 11 Comments »
Posted on January 22, 2020 by Sitemaster
A couple of weeks ago, the full report on the Men’s Eating and Living (MEAL) study was published in the Journal of the American Medical Association. It has generated a lot of discussion, some of which is distinctly misguided. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active, diet, eating, living, MEAL, surveillance, vegetables | 6 Comments »
Posted on June 5, 2019 by Sitemaster
In a presentation at the ASCO annual meeting, Dr. Ronald Chen reported that just 32 percent of newly diagnosed men who were initially managed on active surveillance (AS) in North Carolina between 2011 and 2013 were actually managed in compliance with guideline recommended monitoring. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Management, risk, surveillance | 9 Comments »
Posted on May 7, 2019 by Sitemaster
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 4 Comments »
Posted on March 18, 2019 by Sitemaster
Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend. … READ MORE …
Filed under: Uncategorized | Tagged: active, annual meeting, EAU, surveillance | Leave a comment »